Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 10.94
APPY's Cash to Debt is ranked higher than
76% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. APPY: 10.94 )
APPY' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 10.94

Equity to Asset 0.84
APPY's Equity to Asset is ranked higher than
90% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. APPY: 0.84 )
APPY' s 10-Year Equity to Asset Range
Min: -0.05   Max: 0.85
Current: 0.84

-0.05
0.85
F-Score: 4
Z-Score: 1.67
M-Score: -3.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -6113.19
APPY's Operating margin (%) is ranked lower than
52% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. APPY: -6113.19 )
APPY' s 10-Year Operating margin (%) Range
Min: -14454.84   Max: 17.54
Current: -6113.19

-14454.84
17.54
Net-margin (%) -6155.49
APPY's Net-margin (%) is ranked lower than
52% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. APPY: -6155.49 )
APPY' s 10-Year Net-margin (%) Range
Min: -14858.06   Max: 8.99
Current: -6155.49

-14858.06
8.99
ROE (%) -58.96
APPY's ROE (%) is ranked higher than
55% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. APPY: -58.96 )
APPY' s 10-Year ROE (%) Range
Min: -1390.28   Max: -40.1
Current: -58.96

-1390.28
-40.1
ROA (%) -45.99
APPY's ROA (%) is ranked higher than
59% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. APPY: -45.99 )
APPY' s 10-Year ROA (%) Range
Min: -78.91   Max: -30.69
Current: -45.99

-78.91
-30.69
ROC (Joel Greenblatt) (%) -501.08
APPY's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. APPY: -501.08 )
APPY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -509.39   Max: -33.47
Current: -501.08

-509.39
-33.47
Revenue Growth (%) -68.80
APPY's Revenue Growth (%) is ranked higher than
53% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. APPY: -68.80 )
APPY' s 10-Year Revenue Growth (%) Range
Min: -68.8   Max: -2.3
Current: -68.8

-68.8
-2.3
EBITDA Growth (%) -58.40
APPY's EBITDA Growth (%) is ranked higher than
53% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. APPY: -58.40 )
APPY' s 10-Year EBITDA Growth (%) Range
Min: -58.4   Max: 43.8
Current: -58.4

-58.4
43.8
EPS Growth (%) -58.60
APPY's EPS Growth (%) is ranked higher than
51% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. APPY: -58.60 )
APPY' s 10-Year EPS Growth (%) Range
Min: -58.6   Max: 37.8
Current: -58.6

-58.6
37.8
» APPY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

APPY Guru Trades in

APPY Guru Trades in

Q3 2012

APPY Guru Trades in Q3 2012

Jim Simons 45,785 sh (New)
» More
Q4 2012

APPY Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with APPY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.00
APPY's P/B is ranked higher than
88% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. APPY: 2.00 )
APPY' s 10-Year P/B Range
Min: 1   Max: 117.07
Current: 2

1
117.07
EV-to-EBIT -2.51
APPY's EV-to-EBIT is ranked higher than
60% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. APPY: -2.51 )
APPY' s 10-Year EV-to-EBIT Range
Min: -81.4   Max: 0.5
Current: -2.51

-81.4
0.5
Current Ratio 15.24
APPY's Current Ratio is ranked higher than
97% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. APPY: 15.24 )
APPY' s 10-Year Current Ratio Range
Min: 0.31   Max: 18.74
Current: 15.24

0.31
18.74
Quick Ratio 15.24
APPY's Quick Ratio is ranked higher than
97% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. APPY: 15.24 )
APPY' s 10-Year Quick Ratio Range
Min: 0.08   Max: 18.74
Current: 15.24

0.08
18.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.40
APPY's Price/Net Cash is ranked higher than
99% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. APPY: 2.40 )
APPY' s 10-Year Price/Net Cash Range
Min: 1.76   Max: 51.79
Current: 2.4

1.76
51.79
Price/Net Current Asset Value 2.40
APPY's Price/Net Current Asset Value is ranked higher than
98% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. APPY: 2.40 )
APPY' s 10-Year Price/Net Current Asset Value Range
Min: 1.76   Max: 48.57
Current: 2.4

1.76
48.57
Price/Tangible Book 2.20
APPY's Price/Tangible Book is ranked higher than
90% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. APPY: 2.20 )
APPY' s 10-Year Price/Tangible Book Range
Min: 1.52   Max: 97.5
Current: 2.2

1.52
97.5
Earnings Yield (Greenblatt) -39.10
APPY's Earnings Yield (Greenblatt) is ranked higher than
50% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. APPY: -39.10 )
APPY' s 10-Year Earnings Yield (Greenblatt) Range
Min: -39.1   Max: 530.3
Current: -39.1

-39.1
530.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AP4B.Germany,
Venaxis Inc was organized on July 24, 2000, as a Colorado corporation. In December 2012, the Company's name was changed to Venaxis, Inc., from AspenBio Pharma, Inc. The Company is engaged in development and commercialization of products that address unmet diagnostic and therapeutic needs. The Company's product candidate, APPY1, is designed to be a novel blood-based diagnostic test that, if successfully cleared to be marketed by the United States Food and Drug Administration (FDA), will aid, through the test's negative predictive value, in the evaluation of low risk patients initially suspected of having acute appendicitis, thereby helping address the difficult challenge of triaging possible acute appendicitis patients in the hospital emergency department or urgent care settings. The APPY1, is intended to be used by emergency department and urgent care physicians to aid them in the evaluation of possible appendicitis in children, adolescent and young adult patients (ages 2 - 20) that present with abdominal pain. The FDA has regulatory marketing authority in the United States over its APPY1 products. The Company operates under ISO9001-4385 standards for cGMP manufacturing of medical devices. The Company is subject to various environmental laws pertaining to the disposal of hazardous medical waste. It contracts for disposal of hazardous waste with a licensed disposal facility.
» More Articles for APPY

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Nov 05 2010 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Aug 05 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Jul 31 2010 
advise??? Apr 28 2010 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Nov 05 2009 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Aug 07 2009 
AspenBio Pharma Inc. (APPY) CEO Daryl Faulkner buys 10,000 Shares May 21 2009 
AspenBio Pharma Inc. (APPY) COO & Chief Medical Officer Robert Frederick Caspari buys 3,200 Shares May 19 2009 

More From Other Websites
VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 08 2014
Venaxis Files Response to FDA's Request for Additional Information Dec 03 2014
VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 03 2014
Venaxis, Inc. (APPY) in Focus: Stock Adds 7.6% in Session Nov 26 2014
VENAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 20 2014
VENAXIS, INC. Financials Nov 19 2014
Venaxis to Present at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum Nov 13 2014
10-Q for Venaxis, Inc. Nov 12 2014
VENAXIS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2014
Venaxis’ APPY1 Test Trial Results Presented by Dr. David S. Huckins, M.D., at ACEP14 Oct 27 2014
Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ACEP14 Oct 27 2014
Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14 Oct 14 2014
Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14 Oct 14 2014
Venaxis to Present at September Investor Conferences Aug 28 2014
VENAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 14 2014
VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 11 2014
VENAXIS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
Venaxis Announces Regulatory and Market Development Progress Aug 11 2014
Venaxis to Provide Business Update, including FDA Submission Update Aug 07 2014
Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference Aug 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK